基于肿瘤个体化治疗药物筛选的异种移植模型评价策略  

Evaluation strategy of patient-derived xenograft models based on drug-screening of individualized treatment

作　　者：张贺[1,2] 陈薛 谭邓旭 师长宏 ZHANG He;CHEN Xue;TAN Dengxu;SHI Changhong(Department of Medical Administration,the General Hospital of Shenyang Military Region,Shenyang 110015,China;Laboratory Animal Center,the Air Force Medical University,Xi＇an 710032)

机构地区：[1]原沈阳军区总医院医务部,沈阳110015 [2]空军军医大学实验动物中心,西安710032

出　　处：《中国实验动物学报》2018年第4期523-527,共5页Acta Laboratorium Animalis Scientia Sinica

基　　金：国家自然科学基金(No.31572340;No.31772546);军队实验动物专项课题(No.SYDW2016-006)~~

摘　　要：肿瘤组织异种移植(PDX)模型在遗传学、病理学和生物学特性等方面与患者的原发肿瘤具有较好的相似性,药物临床反应一致性高,在肿瘤个体化治疗领域显示出良好的应用前景。利用PDX模型开展肿瘤靶向药物筛选可有效指导临床用药。本文针对用于化疗药物筛选的PDX模型评价策略进行综述,总结了建模标准和质量控制要求,提出组织形态学、测序分析、特异性标志物和STR检测四种模型溯源性评价方法,综合衡量药物毒性作用、肿瘤体积变化趋势和TGD数学模型结果进行疗效评价,为PDX模型指导肿瘤个体化治疗提供良好的应用策略。Patient-derived xenograft（ PDX） models have high consistency with their primary tumors in terms of genetics,pathology,and biological characteristics. Being perfect in clinical response to drugs,this model shows a good prospect in tumor individualized treatment. It can be used to screen tumor target drug and effectively guide clinical medication. In this review,we focused on the evaluation strategy of PDX models based on chemotherapeutics screening,summarized the standards and quality control requirements of PDX models. We proposed four different ways to evaluate the traceability of models,including histological detection,sequencing analysis,tumor specific marker determination and short tandem repeat（ STR） testing. Furthermore,chemotherapeutics effect can be evaluated by measuring drug toxicity,changes of tumor volume and establishment of TGD mathematical model. All these method applied in the PDX models provide perfect strategy for guiding tumor individualized treatment.

关 键 词：异种移植模型 溯源性 毒性 疗效评价 

分 类 号：Q95-33[生物学—动物学]